MMI Launches REMIND Trial Using Symani System
JACKSONVILLE, FL, May 04, 2026 Medical Microinstruments (MMI) has successfully treated the first patient in its FDA-approved REMIND clinical...
Alzheimer’s Disease
Advertisement
AC Immune Advances ACI-24 Alzheimer’s Trial Expansion
LAUSANNE, Switzerland, April 2026 AC Immune SA announced continued progress in its Phase 1b/2 ABATE clinical trial evaluating ACI-24,...
Axsome Therapeutics Secures FDA Approval for AUVELITY in Alzheimer’s Agitation
NEW YORK, April 30, 2026 LAxsome Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has...
IGC Pharma Strengthens CALMA Trial Through Caregiver Outreach
POTOMAC, Maryland, April 28, 2026 IGC Pharma, Inc. has announced expanded caregiver engagement efforts as its Phase 2 CALMA...
Alzamend Reports Phase II AL001 Brain Data Gains
ATLANTA, United States, April 7, 2026 Alzamend Neuro, Inc. announced encouraging pharmacodynamic data from its Phase II clinical trial...
Advertisements
Tiziana Life Sciences Nasal Therapy Boosts Brain Health
Boston, MA, USA – April 1, 2026 In a promising development for age-related cognitive decline and neurodegenerative disorders, Tiziana...
Eisai and Biogen Report Strong LEQEMBI Long-Term Adherence Data
Copenhagen, Denmark | March 23, 2026 New real-world evidence presented at the AD/PD™ 2026 conference highlights that LEQEMBI® (lecanemab-irmb)...
IGC Pharma Expands Phase 2 CALMA Alzheimer’s Trial
POTOMAC, Md., Feb. 9, 2026 — IGC Pharma, Inc. announced the expansion of its ongoing Phase 2 CALMA clinical...
TML-6 Advances to Global Phase 2 Alzheimer’s Trials
TAINAN, Taiwan, Feb. 9, 2026 — MerryLife Biomedical Inc. announced positive Phase 1 clinical findings for TML-6, its investigational...
FDA Clears Neurophet AQUA AD Plus in Alzheimer’s AI
Seoul, South Korea — February 6, 2026 Neurophet has announced that the U.S. Food and Drug Administration (FDA) has...
Advertisement
